|
February 8, 2010
|
| 09:00 EDT |  | STJ |
| theflyonthewall.com: | On The Fly: Analysts Downgrade Summary | | MOST NOTEWORTHY: Dun & Bradstreet (DNB), Metro Bancorp (METR) and Airgas (ARG) were today's noteworthy downgrades: JP Morgan downgraded Dun & Bradstreet to Neutral from Overweight to reflect a lack of positive catalysts. The firm lowered its target price on shares to $80 from $87. Janney Montgomery downgraded Metro Bancorp to Neutral from Buy following the company's Q4 results and lowered its target price on shares to $14 from $20. Baird downgraded Airgas to Neutral from Outperform. The firm believes the proposed acquisition by Air Products (APD) will get done...OTHER DOWNGRADES: Petrohawk Energy (HK) was downgraded to Market Perform from Outperform at Bernstein. AMB Property (AMB) was lowered to Neutral from Outperform at Credit Suisse. St. Jude Medical (STJ) was downgraded to Conviction Sell from Sell at Goldman. :theflyonthewall.com |
|
| 06:36 EDT |  | STJ |
| theflyonthewall.com: | St. Jude Medical downgraded to Conviction Sell from Sell at Goldman | | Target $35. :theflyonthewall.com |
|
|
February 4, 2010
|
| 09:02 EDT |  | STJ |
|
|
February 3, 2010
|
| 08:00 EDT | | STJ |
| theflyonthewall.com: | St. Jude Medical announces IRASE AF clinical trial | | St. Jude Medical announced it has received an Investigational Device Exemption from the U.S. Food and Drug Administration to begin enrollment in the IRASE AF trial, a multicenter, randomized, single-blind study evaluating the safety and efficacy of the company’s Duo 12 port open irrigated catheter ablation system for treatment of Atrial Fibrillation. AF is the most common cardiac arrhythmia, affecting an estimated 3.3 million Americans and millions more worldwide. :theflyonthewall.com |
|
|
February 2, 2010
|
| 12:57 EDT |  | STJ |
|
| 10:04 EDT |  | STJ |
|
|
January 28, 2010
|
| 07:45 EDT |  | STJ |
|
|
January 27, 2010
|
| 10:48 EDT | | STJ |
|
| 09:21 EDT | | STJ |
|
| 09:20 EDT | | STJ |
| theflyonthewall.com: | St. Jude Medical: Q4 sales of neuromodulation products were $94M | | St. Jude Medical sales of neuromodulation products were $94 million in the fourth quarter of 2009, up 21 percent from the comparable quarter of 2008 :theflyonthewall.com |
|
| 09:19 EDT | | STJ |
|
| 09:17 EDT | | STJ |
| theflyonthewall.com: | St. Jude Medical:Total Cardiac Rhythm Management sales were $698M, up 3% | | Total Cardiac Rhythm Management sales, which include implantable cardioverter defibrillator-ICD-and pacemaker products, were $698 million for the fourth quarter of 2009, a 3 percent increase compared to the fourth quarter of 2008. After adjusting for the impact of foreign currency, total CRM sales decreased 1 percent. Total CRM product sales for the full-year 2009 were $2.769 billion, representing a 3 percent increase over 2008. On a currency neutral basis, total CRM sales grew 5 percent over the prior year :theflyonthewall.com |
|
| 07:34 EDT |  | STJ |
| theflyonthewall.com: | St. Jude Medical sees Q1 EPS 66c-68c vs. consensus s65c | | Sees FY10 EPS $2.71-$2.76 vs. consensus $2.71. :theflyonthewall.com |
|
| 07:33 EDT | | STJ |
|
Subscribe for More Information